DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 hour ago

GEHC·GE HealthCare Technologies Inc.

$.
-. (-.%)
High
$64.69
Open
$64.23
Market Cap
29.22B
52W High
$89.77
Low
$63.50
P. Close
$64.23
P/E
15.30
52W Low
$58.75
Fwd P/E
11.98
Mean Target
-
Technical Score (1D)
27
SELL
News Sentiment
54
MIXED
GE HealthCare Technologies recently launched new AI-driven medical imaging and workflow solutions, including the iRT workflow for radiation therapy, and showcased updated MR systems at recent conferences. This strategic emphasis on AI and improved clinical efficiency aims to enhance research partnerships and promote sustainability within the imaging sector. Concurrently, UBS analysts revised their rating on GEHC from Sell to Neutral, lowering their price target to $69, indicating a recalibration of near-term expectations. Argus Research also adjusted its price target to $80 from $95, while maintaining a 'Buy' rating, suggesting a mixed analyst outlook on valuation. These developments follow a period where GEHC experienced a notable price slide, prompting evaluations of its current valuation and market positioning. The company had previously revised its full-year guidance downwards due to inflationary cost pressures, though it maintained confidence in its long-term growth narrative driven by innovation and improving order trends. Management is pursuing capital management and restructuring initiatives, including share buybacks and strategic acquisitions, to support future margin expansion. Investors are also monitoring options market activity for GEHC, which has shown increased activity suggesting potential shifts in investor sentiment or expectations.
Earnings Summary
GE HealthCare Technologies Inc. is a global leader in the Healthcare sector, specifically within the Medical Devices industry, focusing on diagnostic imaging, patient monitoring, and pharmaceutical diagnostics. The company provides innovative products, services, and digital solutions aimed at improving patient care across various clinical areas, with a diverse portfolio including advanced imaging systems and patient monitoring equipment. In its most recent reported quarters, GEHC demonstrated mixed performance against analyst expectations. For Q1 2026, the company reported actual EPS of $0.99, missing the estimate of $1.04997, while revenue of $5.131 billion exceeded the estimate of $5.027 billion. This followed Q4 2025, where actual EPS of $1.44 slightly beat the estimate of $1.4263, and revenue of $5.698 billion narrowly missed the estimate of $5.723 billion. Prior to this, Q3 2025 saw actual EPS of $1.07 surpassing the estimate of $1.04689, and Q2 2025 reported actual EPS of $1.06 against an estimate of $0.9185. The company's earnings history shows a pattern of beating EPS estimates in three of the last four reported quarters (Q2 2025, Q3 2025, Q4 2025), with a miss in Q1 2026. Revenue estimates were only provided for the last three quarters, showing a beat in Q1 2026 and misses in Q4 2025 and Q3 2025 (though Q3 revenue data was not explicitly provided for comparison against estimate). Recent news highlights GE HealthCare's strategic focus on innovation, with the launch of new AI-driven medical imaging and workflow solutions, including the iRT workflow for radiation therapy, and the showcasing of updated MR systems. These developments aim to enhance clinical efficiency and potentially unlock new revenue streams. Concurrently, analyst sentiment has shown some recalibration, with UBS upgrading the stock to Neutral from Sell, though with a lowered price target. Investors will be watching for the adoption rates of new AI and MR technologies and any further commentary on the company's financial performance and market positioning in the upcoming quarters, particularly in light of recent guidance revisions and ongoing restructuring initiatives.

EPS

EstBeatMiss
$0.83$1.01$1.18$1.35$1.52Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.03 - -
Q1'26$1.05$0.99-5.7%
Q4'25$1.43$1.44+1.0%
Q3'25$1.05$1.07+2.2%
Q2'25$0.92$1.06+15.4%
Q1'25$0.91$1.01+10.6%

Revenue

EstBeatMiss
$4.6B$4.9B$5.3B$5.6B$5.9BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.4B - -
Q1'26$5.0B$5.1B+2.1%
Q4'25$5.7B$5.7B-0.4%
Q3'25 - $5.1B -
Q2'25 - $5.0B -
Q1'25 - $4.8B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

GEHC Stock Snapshot

GEHC is currently trading at $63.70, giving GE HealthCare Technologies Inc. a market cap of 29.22B and a P/E ratio of 15.3. Today's range spans $63.50–$64.69, with shares opening at $64.23 and moving down $0.53 (0.8%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 54/100.

Over the past year GEHC has traded between $58.75 and $89.77 - the current price is +8.4% off the 52-week low and -29.0% from the high.

GEHC scores 27/100 (SELL) and trades at $63.70 - near 52-week lows in the $58.75–$89.77 annual range. Sentiment at 54/100 is neutral. (P/E: 15.3) For a large-cap in Healthcare with 29.22B in capitalization, a SELL signal means that sector rotation money leaving Healthcare will likely exit through names like this first - the combination of negative technicals and neutral news flow is exactly what systematic sector rotation models identify as underweight candidates.

When a large-cap Healthcare name with 29.22B in capitalization prints a SELL signal (27/100) alongside neutral news sentiment (54/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $63.70 (near 52-week lows in the $58.75–$89.77 range), the structural support levels are where that sponsorship question gets answered.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…